Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
about
Recent advances in understanding and treating vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesUpdates in ANCA-associated vasculitisGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Treatment of severe and/or refractory ANCA-associated vasculitis.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.Biologic agents in the treatment of glomerulonephritides.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?The European Vasculitis Society 2016 Meeting Report.Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenColonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].Granulomatosis with Polyangiitis in Children
P2860
Q26747046-83D76A00-6F75-46ED-86F2-51544CE4904EQ26776308-A2D339DF-43FD-4022-A0DA-0276B7A02F04Q28069897-EE8BCAFE-1EE6-4DDB-8073-10E01D5C993AQ30276550-7302C017-5F9A-4636-A4B1-30D40C4613E9Q35887318-30270944-0078-4AD1-AAFE-7B1216343F07Q38219932-4AD7C48F-F9AF-49F1-AF14-889861BDB0D4Q38316279-0A666399-AC84-4321-8440-BFEE0B7C926FQ38327634-ABFE12AE-4FD8-460D-8C22-08C278CA1868Q38334787-117C3F32-8332-417C-92E3-D7EFE936472DQ38514894-F898B11F-0651-443B-B632-29D111209B8AQ38543360-F55324E0-B66E-48E1-B89E-441BCA83BF86Q38965278-0DBBFF69-F715-406F-9392-A46352A5E486Q39088103-DEA781DD-EF32-49DF-9321-0192B7D4074EQ39297333-05001B4E-B685-4075-A411-A6E4980FD1FAQ41208157-56A53AD5-4799-4DF0-A08E-500E2EDBCBD5Q41592598-885A5BC7-21FE-4493-ADD1-C5111E2D3E01Q41605329-511E34F9-3FAD-46FA-BD47-0A1C99C376ABQ42380186-84C1A668-9C36-4A55-8BEB-833311125936Q47107377-864444E4-87D0-4AD7-B20E-2A958D901698Q47163408-BE3C341F-0F83-42C9-8517-0759C3CFF7A0Q48305722-60599EEC-D48D-4154-98CA-76F2F9CC0997Q48592090-E9F75D8D-7F2C-4808-9DAD-B39E4EE76D70Q50076914-EB4AE34B-271B-4D5B-8D00-8059F24BB9D5Q59160666-EF0DD7D5-CA0D-4CD4-9830-349E360A24E7
P2860
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rituximab for induction and ma ...... spective study on 80 patients.
@en
Rituximab for induction and ma ...... spective study on 80 patients.
@nl
type
label
Rituximab for induction and ma ...... spective study on 80 patients.
@en
Rituximab for induction and ma ...... spective study on 80 patients.
@nl
prefLabel
Rituximab for induction and ma ...... spective study on 80 patients.
@en
Rituximab for induction and ma ...... spective study on 80 patients.
@nl
P2093
P2860
P356
P1433
P1476
Rituximab for induction and ma ...... spective study on 80 patients.
@en
P2093
Alexandre Karras
Arnaud Hot
Christophe Deligny
Colas Tchérakian
French Vasculitis Study Group
Gregory Pugnet
Isabelle Marie
Jean-Marc Ziza
Loïc Guillevin
Mehdi Khellaf
P2860
P304
P356
10.1093/RHEUMATOLOGY/KET381
P577
2013-11-26T00:00:00Z